Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Pharmaceutical giant AstraZeneca and Daiichi Sankyo said their antibody drug conjugate reduced the risk of disease progression or death from breast cancer by 72% versus the current breast cancer antibody drug conjugate.
Phase III head-to-head Destiny-breast03 results featured at ESMO Presidential Symposium support 'Enhertu as the potential new standard of care in previously treated patients,' the company said.
In the key secondary endpoint of progression-free survival, or PFS, patients treated with Enhertu 'experienced a three-fold improvement in PFS of 25.1 months versus 7.2 months for T-DM1,' it added.
T-DM1, or trastuzumab emtansine, represented the currently approved drug to treat patients with metastatic breast cancer previously treated with trastuzumab and a taxane.
Destiny-Breast01 phase II trial data, meanwhile, was also presented at ESMO, and showed 'impressive median overall survival of 29.1 months in HER2-positive patients following two or more HER2-based regimens,' the company said.